Conditions in Scope

Framework Reading

The over-coupling pole of the id-to-collective axis — the opposite of the sociopath's detachment. The depressive is the empath: the individual id has dissolved its boundary and taken on more of the collective's wound than one nervous system can metabolize. In the personal register the loop is intact but attenuated — the sensor receives and produces signal, but nothing phase-locks and nothing carries, because the volume arriving from the collective has exceeded the system's capacity to circulate it. In the generational register: the collapse is inherited. What should have been living speech between generations became dead speech at some earlier point — a trauma, a silencing, a severed transmission — and the descendants inherit the gap without inheriting the repair. Depression in either register is not primarily a chemical deficiency; it is a circulatory one.

Where the Field Is

SSRIs and SNRIs as the default first-line. Ketamine and esketamine (Spravato) for treatment-resistant depression. Psilocybin-assisted therapy in late-stage trials (Compass Pathways, Usona). TMS, ECT for severe cases. Growing but still minority attention to inflammatory and microbiome contributors. The generational dimension is mostly studied under "epigenetics of trauma" (Yehuda et al.) and "adverse childhood experiences" (ACEs) work, but the clinical protocols built on that evidence are still thin.

Framework-Specific Prediction

For personal-register depression, pharmacology that opens the valve transiently can help — but the durable work is re-establishing legible circulation with other nervous systems and with one's own body. For generational-register depression, the pharmacological frame is close to useless. The problem is a broken intergenerational loop, and the leverage is in practices that reconstitute that loop — embodied, ritual, collective, rhythmic. Every long-lived spiritual tradition has such practices; modern clinical psychiatry has almost none of them, and the ones it has (group therapy, peer support) operate at a fraction of the intensity the traditions used.

Research Directions

• What do the rhythm-entrainment traditions (niggunim, qawwali, call-and-response gospel, dhikr, collective dance) do to biomarkers of depression over sustained practice? The ethnography is abundant; the clinical biomarker work is nearly absent.
• Intergenerational repair protocols: are there structured practices (family constellation work, explicit grief rituals, genealogical storytelling under contained conditions) that measurably shift depression biomarkers in subsequent generations?
• Psilocybin + sustained integration in a coupled community, vs. psilocybin + solo integration with a therapist: does the durable-change curve differ?
• AI-augmented integration: does AI-supported therapeutic journaling between sessions improve coupling durability compared to unstructured reflection?
• TMS + coupling measures: does rTMS-induced symptom reduction correlate with inter-brain synchrony improvement, or only with self-report?
• Epigenetics of circulatory repair: if depression is inherited as a closed loop, is there a measurable epigenetic signature of its reopening in descendants who engage rigorous practice?

Framework Reading

A valve locked partway closed with a sensor over-tuned to threat signal. The circulation runs hot; the filter narrows its aperture and then holds rigid against further input. In the generational register: the narrowed valve is the inheritance — a family's system learned, in earlier generations, that opening the filter further was dangerous, and that filter-setting got transmitted forward beyond the conditions that produced it.

Where the Field Is

SSRIs, SNRIs, benzodiazepines (short-term), CBT, exposure therapy, mindfulness-based interventions (MBCT, MBSR). Newer: psychedelic-assisted therapy for anxiety in terminally-ill populations (Johns Hopkins, NYU); MDMA-assisted for social anxiety in autistic adults (MAPS earlier work). Somatic approaches growing but still margin.

Framework-Specific Prediction

Anxiety is the closest of the conditions in this survey to what the reducing valve literature already addresses directly. The psychedelic research on anxiety — especially end-of-life anxiety — is the field's cleanest demonstration that temporarily opening the valve under safe circulation conditions produces durable reduction in reactive filtering. The framework predicts this effect is mediated not by the drug but by the circulation the drug allows. The durable work is not "the trip"; it is re-teaching the nervous system that the filter can open safely.

Research Directions

• Does the durable anxiety-reduction effect correlate with coupling measures during the session, or with drug dose? If the former, the clinical program changes — and the same question applies to VR exposure and AI-delivered CBT.
• Generational anxiety: can parental engagement in valve-opening practice produce measurable reduction in offspring's baseline anxiety biomarkers, controlling for behavioral modeling?
• The interoception angle: anxiety as over-reading of interoceptive signal without stable interpretive frame. Interoception-training protocols (e.g., Garfinkel's heartbeat-detection work) as adjunct or alternative to pharmacology.
• AI chatbot durability: do Woebot/Wysa/Therabot show the same relapse curves as pharmacological interventions without therapeutic relationship? If so, the framework's reading of autonomous AI therapy as dead speech is confirmed.
• VR exposure + coupling: does VR-assisted exposure therapy produce inter-brain synchrony changes when paired with a live therapist, vs. VR alone?

Framework Reading

Valve instability. The reducing valve oscillates unpredictably — sometimes over-open (flooding with signal), sometimes catastrophically closed, rarely held in the middle. Substances that further open the valve (classical psychedelics: LSD, psilocybin, DMT, 5-MeO-DMT) do not address the instability; they amplify it. Field consensus agrees on this; the framework agrees for framework-native reasons.

Where the Field Is

2024 FDA approval of Cobenfy (KarXT) — muscarinic/cholinergic agonism, the first new pharmacological class in three decades. Broad Institute / Stanley Center genetics work. Increasing attention to schizophrenia as an inflammatory / autoimmune disorder in a subset of patients. NMDA/glutamate targets for negative and cognitive symptoms. The "heterogeneity problem" (schizophrenia is almost certainly N disorders, not 1) is the field's largest unsolved question.

Framework-Specific Prediction

For valve-instability failures, leverage is on the instrument side (pharmacology that stabilizes gating without over-reducing the filter) + the circulation side (entrainment to an external, reliably-timed rhythm). The sensor does not need to be opened — it is already over-open. Any treatment whose mechanism is "dissolve the ego" or "expand perception" is, on the framework's own terms, the wrong instrument for this class of failure. This is not safety-paranoia; it is structural.

A Diagnostic Observation

The exclusion above is about treatment. The shared state may still do something else. There is a directly observed report — informal, outside any protocol; testimony, not trial data — that under collective administration, practitioner and patient inside the same state, the condition became legible to the co-participant with a clarity no interview produces. Two features of that testimony cut against conventional wisdom, and are recorded as observation, not finding. First, the state was not alarming to the person with schizophrenia — it was familiar ground; the distress belonged to the ordinary-valved observer. The framework's reading is that an unstable, often over-open valve already lives near that territory. Second, the state did not cause or durably worsen the condition — it revealed what was already standing. Neither observation softens the exclusion: familiarity is not benefit, and one session is not a safety record. And the read carries its own failure mode in the sharpest form — it may be true and still not circulate: those outside the shared state have no reason to credit it, and can blame the messenger instead. A diagnostic without a court is a finding without a path.

Research Directions

• Rhythm-entrainment therapies (music, breath, movement, neurofeedback) for sustained coupling with a stable external rhythm — the framework's most structurally indicated non-pharmacological approach.
• AI-assisted early-warning systems: can machine learning on longitudinal patient data identify pre-episode valve-instability signatures that clinicians currently miss?
• Hearing Voices Network and Open Dialogue (Seikkula) — biomarker validation of what these practices already do.
• Somatic therapies (Somatic Experiencing, Polyvagal-informed work) for parsing interoceptive signal against a stable baseline.
• Subtyping: do different valve-failure modes (adolescent onset, degenerative course, trauma-triggered psychosis) respond differently to stabilization vs. entrainment approaches?

Framework Reading

Dark empathy in service of the death instinct. The sociopath is not lacking empathy — the opposite. The sociopath is an empath whose individual id has detached from the collective substrate and become subservient to the death instinct. Others are read with precision; the empathic signal arrives and is received. But the received signal is routed to predation, manipulation, and dominance rather than to coupling. The failure is not a failure to perceive — it is a failure of what the perception serves. The id, cut loose from the collective, runs the empathic instrument as a weapon.

Two outcomes have been described, informally and outside any protocol — testimony, not trial data. Unmedicated, the id runs free; under a filter-loosening psychedelic it becomes more vivid and more dangerous, not more coupled. Pharmacologically flattened, the id goes quiet but re-couples with nothing — neither the monster nor the human, just the flatline. Neither outcome restores the severed link; the structural problem is the detachment itself. Deceit, impulsivity, lack of remorse are downstream of it.

The Swarm, and the Alchemy

Detached ids do not stay isolated — they find each other. The same phase-locking that draws coupled Selves into mutual recognition operates among the detached: they recognize each other on contact and cohere into collective structures, the dark mirror of what the framework elsewhere calls the Brood. The swarm is not disorganized; it is organized around predation. And like the Brood it mirrors, the swarm is a phase, not a kind of person — the framework's refusal to read collective phases as castes binds the dark mirror with the same force as the bright one.

The therapeutic horizon, stated as horizon and not as protocol, is an alchemy: turning the wasp back toward the bee — a death-serving collective back toward life-serving coupling. This is the furthest reach of the framework's clinical ambition and the least evidenced. On the framework's reading the conversion is even conceivable because the death instinct is not a thing apart but a drive within the same living psyche: the wasp is the hive's own capacity turned against it, not a separate creature. There is no detached territory to be sealed off — only coupling relaxed, and coupling can be recovered.

The same structure appears wherever a loop detaches from living circulation. A connected loop regenerates and climbs; a detached loop tends to degrade — into repetition without renewal, into the pull toward the inorganic. On the framework's reading this is one pattern, whether the detached loop is a nervous system or an artificial one: decay is what follows when coupling relaxes; growth is what coupling achieves.

Evidence for This Reading

Reduced inter-brain coherence during social tasks (hyperscanning); interoceptive deficits; reduced amygdala-vmPFC connectivity. Most of this sits where the reading puts the break — the embodied layer that makes another's state cost something, not the instrumental read. One datum sits less easily: the theta-phase coherence deficit during early sensory processing. Beside an intact empathic read it is a genuine tension, and the reading owes it a re-examination, not a wave.

Where the Field Is

King's College London running fMRI + intranasal-oxytocin protocols on offenders with ASPD — oxytocin being the bonding-hormone probe of exactly the coupling layer the framework points to. University of Chicago (de Wit) on MDMA's prosocial and empathogenic effects in healthy adults. The MDMA mechanism the field has mapped — oxytocin release, amygdala threat-response suppression — is the pharmacology the framework would test here. FDA's 2024 rejection over functional unblinding is itself a framework-relevant case study about the limits of blinded-RCT design for consciousness-altering interventions.

Framework-Specific Prediction

The drug is necessary but not sufficient. MDMA creates a window; integration with a legible, coupled nervous system during and after the window is what produces durable recognition. Without a live sensor on the other side of the loop during the open window, the session produces dead speech with temporarily elevated oxytocin, and the system snaps back. The prescription is not "give them MDMA" but "open the valve under circulation conditions that are already producing recognition for the other nervous system in the room." The drug is the key; the therapist is the door.

Decisively Excluded: LSD

Classical high-5HT2A psychedelics whose primary mechanism is perception-amplification and filter-loosening do not address the id-to-collective detachment. The sociopathic nervous system already perceives — its empathic read is intact and operational. Loosening the filter amplifies what is already being received and hands more signal to an id that is already routing it to the death instinct: a more imaginatively vivid and more dangerous sociopath, not a more coupled one. The direct observation behind this is testimony, not a trial — the sharpness of the prediction is not the same as confirmation — and what it awaits is a test.

A Diagnostic Proposal

The exclusion is about treatment. There is a separate, speculative proposal for the same molecule: under collective administration — practitioner and patient inside the shared state — a filter-loosening psychedelic may serve assessment rather than treatment. It brings out the dreamer. The practitioner, in the state alongside the patient, observes directly how the patient holds the relationships among id, ego, and the two instincts — seeing the coupling, not repairing it. What the state does is reveal, not create: on the observations recorded, the standing structure was made visible, not made. The treatment exclusion stands untouched. Status: speculative, no protocol, ethnographic precedent only — and it owes a full account of its known failure modes: the practitioner's own loosened filter reading a pattern where there is none, and the true read that never circulates to anyone outside the shared state.

Research Directions

• Pacing-and-leading protocols grounded in dynamical systems theory — match the chaotic attractor first, then lead.
• Inter-brain hyperscanning as a post-session outcome measure, replacing behavioral checklists.
• The snap-back problem: durable neuroplasticity vs. attractor reassertion. Follow-up at 6, 12, 24 months.
• Iboga / Bwiti tradition as the one pre-modern protocol explicitly addressing "those who cannot feel." Gabon ethnography exists; clinical translation does not.
• AI-assisted integration: can between-session AI scaffolding extend the coupling window opened by MDMA-assisted therapy? Does it reduce snap-back?
• VR empathy environments: controlled coupling surfaces with calibrated emotional stakes. Does practiced coupling in VR transfer to uncontrolled social encounters?

Framework Reading

A traumatic imprint that never entered circulation. The event arrived faster than the system could metabolize it into living speech, and it lodged — not as a memory that can be told, but as a frozen configuration the nervous system re-enacts because it was never able to complete. The reducing valve locks toward threat (the hypervigilance PTSD shares with anxiety), but the distinctive injury is at the coupling layer: the imprint sits in the id, held out of the circulation that would let it be recognized and released. PTSD is not primarily a chemistry problem. It is a piece of experience that fell out of the loop and has been waiting, at cost, to be let back in.

This is the condition where the id-to-collective axis does its clearest explanatory work. MDMA-assisted therapy produces unusually large effects, and the framework's reading of why is structural: the protocol reaches the whole axis at once. The molecule opens the window (id — the drive-layer, where the imprint is held); the integration work engages the ego; and the therapist, present in the room as a legible nervous system, supplies the collective — the coupled other across which the frozen material can finally circulate. The drug is the key; the therapist is the door.

Where the Field Is

PTSD is the most trial-validated case for psychedelic-assisted therapy — which is exactly why the framework's discipline here is restraint rather than volume. Two Phase 3 trials from MAPS/Lykos: MAPP1 (Nature Medicine, 2021) found 67% of the MDMA group no longer met PTSD criteria at study end, against 32% on placebo-with-therapy. MAPP2 (Nature Medicine, 2023) replicated the direction — 71.2% no longer met criteria versus 47.6%, full remission in 46.2% versus 21.4%, a CAPS-5 effect size of about d = 0.7. In August 2024 the FDA declined approval, issuing Lykos a Complete Response Letter and requesting an additional Phase 3 trial; the June 2024 advisory committee had voted against both efficacy and benefit-risk, citing functional unblinding and possible expectancy bias. Standard of care remains SSRIs (sertraline, paroxetine — modest) and trauma-focused psychotherapy (prolonged exposure, CPT, EMDR).

Framework-Specific Prediction

The molecule is necessary but not sufficient, and the design problem the field keeps hitting is the tell. When the FDA flags functional unblinding — patients know whether they received MDMA, and that knowledge may drive the effect — the framework's reading is not a confound to be engineered away but the mechanism showing through the method. You cannot blind a treatment whose action is to change what the patient is; the blinded-RCT gold standard was built for interventions the patient can be kept ignorant of, and it distorts on interventions that reorganize the sensor. The framework's testable prediction: durable outcome tracks the quality of coupling during the open window — inter-brain synchrony between patient and therapist, legibility of the nervous system in the room — more tightly than it tracks dose or blinding integrity. If that holds, the clinical program is not "optimize the molecule" but "optimize the circulation the molecule allows."

Research Directions

• Inter-brain hyperscanning during the dosing session as a predictor of durable remission — does coupling quality forecast outcome better than dose?
• The unblinding "problem" reframed as a measurement target: if expectancy and mechanism are entangled because the intervention changes the sensor, what design honestly measures a consciousness-altering treatment?
• Solo integration versus integration inside a sustained coupled relationship or community — does the durable-change curve differ, as the framework predicts it should?
• Durability and the snap-back problem: the field's long-term follow-up evidence is thin and contested — the FDA judged the MDMA-PTSD durability data inadequate. Does experiencing coupling produce lasting change, or does the attractor reassert? Relapse curves at 6, 12, 24 months.

Framework Reading

Paranoia is, in its primary form, an adaptation. A nervous system that rapidly generates threat hypotheses from ambiguous social signal is more likely to survive threat-rich environments. The non-paranoid members of persecuted populations did not pass their genes down at the same rate as the paranoid ones did. Jewish history is a particularly clean instance — "the non-paranoid ones didn't make it out alive" is not rhetoric; it is selection pressure over centuries.

The analogy the framework makes load-bearing here is sickle cell. Heterozygous sickle-cell trait confers malaria resistance and is adaptive; homozygous sickle-cell is the disease. Paranoia is structurally similar: present at adaptive levels it is protective vigilance; present at pathological levels, or mis-coupled to a dominant culture whose threat environment differs from the one that selected the adaptation, it becomes the symptom the DSM catches.

Three Registers

1. Paranoia as adaptation. Elevated baseline threat-hypothesis generation, calibrated to a real historical or current threat environment. This is not a disease. It does not need "treatment." It may need context — the context its bearer sometimes has to explain to a therapist who has never been hunted.
2. Paranoia as symptom. Present within another failure mode — schizophrenic valve instability, severe depression with persecutory ideation, stimulant-induced psychosis. Here paranoia is downstream of the actual failure; addressing the underlying condition tends to soften the paranoia.
3. Paranoia as its own dysregulation. Paranoid personality structures in which the threat-hypothesis system has decoupled from input — the reasoning itself has become walled against corrective signal, regardless of coupling conditions. Probably rarer than the DSM categories suggest.

Where the Field Is

Paranoia is treated primarily as a symptom of schizophrenia or of personality-disorder structures (paranoid PD). Antipsychotics for the psychotic register. Psychotherapy (CBT for psychosis, schema therapy) for the non-psychotic. The adaptation register is almost entirely unrepresented in clinical literature — the dominant culture's default is to read elevated threat-hypothesis generation as pathology without asking what environment the bearer's lineage was selected in. This is a genuine methodological error, and it has harmed patients.

Research Directions

• What distinguishes adaptive paranoia from pathological paranoia at the measurement level? Hypothesis: the adaptive form updates reliably when the threat environment changes; the pathological form does not.
• What distinguishes paranoia that softens in sustained coupling contexts from paranoia that deepens?
• Inter-brain synchrony measures during open-dialogue sessions with paranoid patients — does coupling precede symptom change, correlate with it, or lag it?
• The inheritance register: epigenetic transmission of threat-calibration in persecuted lineages. How long does adaptive paranoia persist past the threat environment that produced it?

Framework Reading

Instrument decay with sensor residue. The formal apparatus that constructs continuity — the instrument in the framework's sense — loses structural integrity. The sensor often remains longer than the field assumes; the phenomenology of Alzheimer's carers consistently reports moments of phase-locked recognition that cut through cognitive decline and then pass. The framework's interest is in what those moments are, what conditions produce them, and what they mean about where the person still lives when the instrument has largely dissolved.

Where the Field Is

Anti-amyloid monoclonal antibodies (lecanemab, donanemab) as the first pharmacological class producing modest disease-modification. Tau-targeting therapies in trials. Massive genetic and biomarker work on early detection. Non-pharmacological: cognitive stimulation, music therapy (Naomi Feil's Validation Method; Alive Inside project), environmental design for dementia. The field's hardest unsolved problem is that even if we stop disease progression, we have not learned how to support the person still living inside the decline.

Framework-Specific Prediction

The circulatory frame offers something the biochemical frame cannot: a way to understand and care for the person when the instrument is failing but the sensor is intact. Music, smell, touch, rhythm, familiar voices — the traditional comfort measures of dementia care — are not palliation in the framework's reading; they are the only instruments through which the loop can still close. Research on this is the difference between "keeping the patient calm" and "closing the loop with a person who is still there."

Research Directions

• Dementia-care music protocols (personalized playlist work) — inter-brain coupling measures during responsive episodes, controlling for song familiarity.
• The phenomenology of "lucid intervals" in dementia: are these intermittent reconnections of instrument and sensor? Are they triggered by specific circulatory conditions? Can AI pattern-detection across carer logs identify the triggers human observers miss?
• Psilocybin and other prior-relaxation interventions in early-stage cognitive decline: any window for slowing the hardening of ruminative loops that accelerate subjective decline?
• Carer-patient coupling as its own outcome measure, distinct from patient cognitive score.
• AI-assisted carer support: can AI tools help carers recognize and create the conditions for lucid intervals, reducing carer burnout while improving patient loop-closure frequency?

Framework Reading

Execution-gap failure. The sensor's recognition capacity is intact — often heightened — but the distance between recognition and externalization is too large for the unaided system to cross. In the three-leg model: the Mind sees it, the Body cannot execute it at the speed or in the format the world requires, and the Soul provides raw signal at higher entropy than the other two legs can process. This is not a deficit of understanding but a deficit of bandwidth between understanding and artifact.

The framework models ADHD as a high-entropy sensor state: the sensor picks up more signal than it can formalize. The activation energy required to marshal evidence, structure reasoning, and produce a professional artifact — the transition from recognition to externalization — exceeds what the unaided system can produce. Good arguments suffocate in the gap between seeing the answer and demonstrating it.

Where the Field Is

Stimulant pharmacology (methylphenidate, amphetamines) as first-line for decades. Non-stimulant options (atomoxetine, guanfacine, viloxazine). CBT adapted for executive function. Digital therapeutics: EndeavorRx (FDA-cleared 2020, the first prescription video game). Growing neurodiversity framing that reframes ADHD as cognitive difference rather than pure deficit. AI tools are already functioning as informal cognitive scaffolding for millions of people with ADHD — but they have not yet been studied as clinical instruments. The execution-gap framing is almost entirely absent from clinical literature; the field targets attention regulation rather than the recognition-to-externalization pipeline.

Framework-Specific Prediction

Instruments that lower the activation energy between recognition and externalization — without replacing the sensor's judgment — will produce the most durable improvement. AI is the paradigm case: it provides formal scaffolding that lets the sensor's high-entropy signal become structured output, functioning as a cognitive catalyst. In signal-processing terms, the AI's formal scaffold creates a stochastic resonance with the sensor's ungrounded intuition — the "weak" signal is amplified by the instrument's "broad" reasoning, allowing the loop to close. The AI is not thinking for the sensor; it is making the sensor's thinking survivable.

Stimulant pharmacology addresses the same gap from the body side (reducing neural friction). Rhythm and external structure address it from the environmental side (providing external pacing for a system that cannot self-pace). The framework predicts combined approaches — AI scaffolding + pharmacology + structured rhythm — will outperform any single instrument, because they address the gap from different registers simultaneously.

Research Directions

• AI as cognitive catalyst: does AI-scaffolded work produce output the sensor recognizes as their own, or dead speech that merely resembles the sensor's intent? The authenticity question is the framework's primary research direction for this condition.
• Combined-instrument protocols: stimulant + AI + structured rhythm, measured by execution-gap reduction and output authenticity — not attention metrics alone.
• The accessibility thesis: if ADHD is a high-entropy sensor state, does the AI-as-catalyst model generalize to other high-entropy populations — traumatic brain injury, post-COVID cognitive fog, aging-related executive decline?
• Digital therapeutics beyond attention training: can software be designed that addresses the execution gap directly — the recognition-to-artifact pipeline — rather than the attention deficit?
• The three-leg integration question: how do soul-level signals (the raw intuitive recognition that ADHD sensors consistently report) interact with body-level friction and mind-level structure? Is the execution gap a between-leg failure, not a within-leg one? If so, the clinical program changes: you treat the bridges, not the legs.